null

null

null

null

null

null

null

null

null

0.23x Total Debt / Equity (Conservative)

Low direct sensitivity; Corbus carries minimal long-term debt (~$0 drawn on credit facilities), primary burn is equity-funded, so 200bps rate move negligibly impacts interest expense but raises equity dilution cost

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API synthesis partners in China (active pharmaceutical ingredient sourcing) and European CROs concentrated in UK/Germany post-Brexit regulatory divergence

Minimal international revenue; clinical-stage company with USD-denominated operations, sovereign currency devaluation exposure is near-zero as no commercial product revenues exist

Effectively US-only operational footprint; clinical trials run in select EU/international sites but all revenue and cash reserves are USD-denominated with negligible FX exposure

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single CRO (likely Covance/Labcorp or ICON) manages pivotal trials; substitution mid-trial would cost 12-18 months and ~$10M+, representing non-substitutable operational dependency

Cloud termination would cause moderate disruption; clinical data management and bioinformatics pipelines depend on cloud, but core IP (drug compounds) is non-digital and unaffected

Biotech drug developer; pre-revenue clinical-stage company with no secondary business model, all value creation is pipeline-dependent milestone-driven

Low API coupling risk; not a software company; primary external coupling is to clinical research organizations and regulatory databases, not software APIs

Not applicable; Corbus is a publicly traded equity, not a token or investment contract; standard equity security, Howey Test inapplicable to revenue model

Very High

Moderate GDPR exposure from EU clinical trial patient data; CCPA exposure minimal; clinical data governed by FDA/EMA frameworks, GDPR compliance required for EU trial sites

Negligible antitrust risk; clinical-stage company with no marketed products, no market share, and no distribution agreements that could trigger competition authority scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue; 100% transactional/milestone-based; company is pre-commercial with no product sales, revenue consists of collaboration payments and grants when received

Future monetization via drug royalties, licensing milestones, or outright acquisition; current monetization is equity and debt capital raises, not product revenue

No commercial pricing architecture exists; pricing power will be determined post-approval by payer negotiations, orphan drug status, and competitive landscape for oncology/fibrosis indications

Potentially high if pipeline drugs achieve orphan designation or first-in-class status; specialty biotech pricing typically $50K-$200K/year annually for comparable indications

Pharma gross margins target 80-90%+ at commercial scale; pre-revenue stage means current gross margin is negative/undefined

No free-rider problem; proprietary drug IP cannot be freely replicated; no subscription or platform model susceptible to churn or free-rider leakage

Revenue growth is highly sublinear to headcount; commercialization can be outsourced to contract sales organizations; R&D headcount ~40-60 FTEs drives disproportionate pipeline value

Marginal cost of revenue growth is capital (clinical trial spend), not headcount; doubling pipeline breadth requires ~doubling capex but not proportional employee growth

Not applicable; Corbus operates no franchise network

At 10x scale (post-commercialization), CAC irrelevant for rare disease/oncology; physician adoption driven by medical affairs and KOL engagement, not traditional CAC models

No network effects present; drug efficacy and physician adoption do not compound with user scale; value is purely clinical outcome and IP-driven

AI displacement risk low for core drug discovery; AI may accelerate target identification but cannot replace clinical trial execution or FDA regulatory expertise

Moderate recession resistance; oncology/fibrosis drugs face inelastic demand post-approval, but funding rounds and partnership deals are more difficult in risk-off environments

Pharmaceutical/biotech licensing partners and acquirers; no end-patient revenue yet; primary 'customers' are institutional partners and future payers

Government/NIH grant sources and public equity investors as capital providers; secondary revenue source from non-dilutive grants for rare disease programs

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is entirely forward-looking; 95%+ of spend directed to clinical trial execution and drug development; zero legacy infrastructure, no reallocation tension

0001595097

CRBP